Molecular Quantum Solutions Raises €600k in Pre-seed Round to Help Pharma and Chemical Companies Use Quantum

Insider Brief

• Molecular Quantum Solutions received €600,000 in a pre-seed fundraise.
• The round was led by Scale Capital, alongside Rockstart and Stokbro Invest.
• Molecular Quantum Solutions plans used the funds to convert the tool stack they have developed to a SaaS solution for the pharma and chemical industry.

PRESS RELEASE — Rockstart, global early stage VC and accelerator, announces its co-investment in Molecular Quantum Solutions, a Rockstart Emerging Tech portfolio company. The €600k round was led by Scale Capital, alongside Rockstart and Stokbro Invest. With the new funding, Molecular Quantum Solutions (MQS) plans to convert the tool stack they have developed to a SaaS solution for the pharma and chemical industry.

MQS’ in-house team of quantum physicists, chemical engineers, backend and full-stack developers, and business developers offer advanced computational tools to accelerate R&D efforts in the pharmaceutical, biotech, and chemical sectors. Their cutting-edge tools leverage supercomputers and quantum computing technology, utilizing computational models and algorithms to rapidly and efficiently calculate material and chemical properties. The pharma and biopharma industries typically invest between approximately 20 and 60 billion USD in drug formulation and manufacturing upscaling phases. With MQS, users can now screen and evaluate new materials for applications such as batteries, green solvents, pharmaceutical drugs, and biodegradable plastics without the need for expensive laboratory experiments.

“Over the last three years, we have built a solid infrastructure to run computationally demanding quantum chemistry calculations in the cloud and solve industrial relevant use cases. Further, we have developed novel quantum computing methods which we are integrating into our classical calculation pipeline. We have several collaborations ongoing with quantum computing research institutions and companies. We are now set to push into a worldwide market with our cloud products stack.” — Mark Nicholas Jones, CEO/CTO, Molecular Quantum Solutions

“We are thrilled to partner with Mark and the team at MQS and help them get to the next stage. We have been very impressed with their product and commercial achievements so far, and sincerely believe that their quantum chemistry simulation platform will disrupt the drug formulation space. We think the company stands out from the competition and that they have a clear value proposition for accelerating the pharma R&D pipeline. We are excited to start the work!” — Joachim Schelde, Investment Associate, Scale Capital

“Increasing computing power will play a pivotal role in tackling global issues and shortcutting its time to market can significantly contribute to worldwide problem-solving. We invested in Molecular Quantum Solutions (MQS) to streamline computing power and drive change in Industry 4.0 & advanced analytics development. The MQS team works relentlessly to build highly complex quantum chemistry solutions in the space of supercomputing and quantum computing and we’re excited to have joined their journey early on.” — Michael Bjørnlund, Managing Partner, Rockstart Emerging Tech:

The Rockstart Emerging Tech fund is Rockstart’s third fund launched in 2022. Rockstart Emerging Tech has invested in 11 startups since its launch last year. Other fund investments include Forloop, Nova Money, Insai, Rightstars, Tech2B , Contribe , CatchScan, AuthicLabs , Purple Gaze, and Viezo.